Cancer of the ampulla of Vater: Analysis of the whole genome sequence exposes a potential therapeutic vulnerability

Genome Medicine

Volumn 4, Issue 7, 2012, Pages

  Demeure, Michael J ^a,b   Craig, David W ^a   Sinari, Shripad ^a   Moses, Tracy M ^a   Christoforides, Alexis ^a   Dinh, Jennifer ^a   Izatt, Tyler ^a   Aldrich, Jessica ^a   Decker, Ardis ^a   Baker, Angela ^a   Cherni, Irene ^a   Watanabe, April ^a   Koep, Lawrence ^c   Lake, Douglas ^d   Hostetter, Galen ^a   Trent, Jeffrey M ^a   Von Hoff, Daniel D ^a,b   Carpten, John D ^a  

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^b Virginia G Piper Cancer Center   (United States)

^c BANNER GOOD SAMARITAN MEDICAL CENTER   (United States)

^d ARIZONA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SMAD4 PROTEIN;

ADULT; AMPULLA OF VATER CANCER; ARTICLE; BILE DUCT CANCER; BLOOD ANALYSIS; CARCINOGENESIS; CASE REPORT; DNA DETERMINATION; GENE SEQUENCE; GENE STRUCTURE; GENOME; HUMAN; HUMAN TISSUE; MALE; PANCREAS CANCER; PANCREATICODUODENECTOMY; PRIORITY JOURNAL; SMALL INTESTINE CANCER; SOMATIC MUTATION; VATER PAPILLA;

EID: 84863191007     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm357     Document Type: Article

References (31)

1. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010, 362:1273-1281. 10.1056/NEJMoa0908721, 20375404.
2. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355:2408-2417. 10.1056/NEJMoa062867, 17151364.
3. Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, Corless CL, Fletcher CD, Roberts PJ, Heinz D, Wehre E, Nikolova Z, Joensuu H. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008, 26:620-625. 10.1200/JCO.2007.13.4403, 18235121.
4. Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Mackey HM, Lum BL, Darbonne WC, Marsters JC, de Sauvage FJ, Low JA. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009, 361:1164-1172. 10.1056/NEJMoa0905360, 19726763.
5. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010, 363:809-819. 10.1056/NEJMoa1002011, 20818844.
6. Tuch BB, Laborde RR, Xu X, Gu J, Chung CB, Monighetti CK, Stanley SJ, Olsen KD, Kasperbauer JL, Moore EJ, Broomer AJ, Tan R, Brzoska PM, Muller MW, Siddiqui AS, Asmann YW, Sun Y, Kuersten S, Barker MA, De La Vega FM, Smith DI. Tumor transcriptome sequencing reveals allelic expression imbalances associated with copy number alterations. PLoS One 2010, 5:e9317. 10.1371/journal.pone.0009317, 2824832, 20174472.
7. Robbins CM, Tembe WA, Baker A, Sinari S, Moses TY, Beckstrom-Sternberg S, Beckstrom-Sternberg J, Barrett M, Long J, Chinnaiyan A, Lowey J, Suh E, Pearson JV, Craig DW, Agus DB, Pienta KJ, Carpten JD. Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. Genome Res 2011, 21:47-55. 10.1101/gr.107961.110, 3012925, 21147910.
8. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, DePristo MA. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010, 20:1297-1303. 10.1101/gr.107524.110, 2928508, 20644199.
9. Stajich JE, Block D, Boulez K, Brenner SE, Chervitz SA, Dagdigian C, Fuellen G, Gilbert JG, Korf I, Lapp H, Lehvaslaiho H, Matsalla C, Mungall CJ, Osborne BI, Pocock MR, Schattner P, Senger M, Stein LD, Stupka E, Wilkinson MD, Birney E. The Bioperl toolkit: Perl modules for the life sciences. Genome Res 2002, 12:1611-1618. 10.1101/gr.361602, 187536, 12368254.
10. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R. The Sequence Alignment/Map format and SAMtools. Bioinformatics 2009, 25:2078-2079. 10.1093/bioinformatics/btp352, 2723002, 19505943.
11. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008, 3:1101-1108. 10.1038/nprot.2008.73, 18546601.
12. A map of human genome variation from population-scale sequencing. Nature 2010, 467:1061-1073. 10.1038/nature09534, 3042601, 20981092.
13. Scarpa A, Zamboni G, Achille A, Capelli P, Bogina G, Iacono C, Serio G, Accolla RS. ras-family gene mutations in neoplasia of the ampulla of Vater. Int J Cancer 1994, 59:39-42. 10.1002/ijc.2910590109, 7927901.
14. Howe JR, Klimstra DS, Cordon-Cardo C, Paty PB, Park PY, Brennan MF. K-ras mutation in adenomas and carcinomas of the ampulla of vater. Clin Cancer Res 1997, 3:129-133.
15. Ng PC, Henikoff S. Predicting deleterious amino acid substitutions. Genome Res 2001, 11:863-874. 10.1101/gr.176601, 311071, 11337480.
16. Ng PC, Henikoff S. SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res 2003, 31:3812-3814. 10.1093/nar/gkg509, 168916, 12824425.
17. Howe JR, Klimstra DS, Moccia RD, Conlon KC, Brennan MF. Factors predictive of survival in ampullary carcinoma. Ann Surg 1998, 228:87-94. 10.1097/00000658-199807000-00013, 1191432, 9671071.
18. Yeo CJ, Sohn TA, Cameron JL, Hruban RH, Lillemoe KD, Pitt HA. Periampullary adenocarcinoma: analysis of 5-year survivors. Ann Surg 1998, 227:821-831. 10.1097/00000658-199806000-00005, 1191384, 9637545.
19. Monson JR, Donohue JH, McEntee GP, McIlrath DC, van Heerden JA, Shorter RG, Nagorney DM, Ilstrup DM. Radical resection for carcinoma of the ampulla of Vater. Arch Surg 1991, 126:353-357. 10.1001/archsurg.1991.01410270099016, 1998478.
20. O'Connell JB, Maggard MA, Manunga J, Tomlinson JS, Reber HA, Ko CY, Hines OJ. Survival after resection of ampullary carcinoma: a national population-based study. Ann Surg Oncol 2008, 15:1820-1827. 10.1245/s10434-008-9886-1, 18369675.
21. Shutze WP, Sack J, Aldrete JS. Long-term follow-up of 24 patients undergoing radical resection for ampullary carcinoma, 1953 to 1988. Cancer 1990, 66:1717-1720. 10.1002/1097-0142(19901015)66:8<1717::AID-CNCR2820660811>3.0.CO;2-4, 2208026.
22. Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, Zahurak M, Goodman SN, Sohn TA, Hruban RH, Yeo CJ, Kern SE. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997, 57:1731-1734.
23. Demeure MJ, Doffek KM, Komorowski RA, Wilson SD. Adenocarcinoma of the pancreas: detection of occult metastases in regional lymph nodes by a polymerase chain reaction-based assay. Cancer 1998, 83:1328-1334. 10.1002/(SICI)1097-0142(19981001)83:7<1328::AID-CNCR9>3.0.CO;2-E, 9762933.
24. Suto T, Sugai T, Habano W, Uesugi N, Kanno S, Saito K, Nakamura S. Allelotype analysis of the PTEN, Smad4 and DCC genes in biliary tract cancer. Anticancer Res 2002, 22:1529-1536.
25. Sawai H, Yasuda A, Ochi N, Ma J, Matsuo Y, Wakasugi T, Takahashi H, Funahashi H, Sato M, Takeyama H. Loss of PTEN expression is associated with colorectal cancer liver metastasis and poor patient survival. BMC Gastroenterol 2008, 8:56. 10.1186/1471-230X-8-56, 2611992, 19036165.
26. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio-Donahue C, Eshleman JR, Kern SE, Hruban RH, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321:1801-1806. 10.1126/science.1164368, 2848990, 18772397.
27. Paez J, Sellers WR. PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling. Cancer Treat Res 2003, 115:145-167.
28. Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev 2001, 15:807-826. 10.1101/gad.887201, 11297505.
29. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008, 7:1851-1863. 10.1158/1535-7163.MCT-08-0017, 18606717.
30. Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008, 68:8022-8030. 10.1158/0008-5472.CAN-08-1385, 18829560.
31. Von Hoff DD, Stephenson JJ, Rosen P, Loesch DM, Borad MJ, Anthony S, Jameson G, Brown S, Cantafio N, Richards DA, Fitch TR, Wasserman E, Fernandez C, Green S, Sutherland W, Bittner M, Alarcon A, Mallery D, Penny R. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 2010, 28:4877-4883. 10.1200/JCO.2009.26.5983, 20921468.